m6A-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with LUAD
Lung adenocarcinoma (LUAD) is the most frequent subtype of lung cancer worldwide. However, the survival rate of LUAD patients remains low. N6-methyladenosine (m6A) and long noncoding RNAs (lncRNAs) play vital roles in the prognostic value and the immunotherapeutic response of LUAD. Thus, discerning...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-06-01
|
| Series: | Molecular Therapy: Nucleic Acids |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2162253121000974 |
| _version_ | 1818641762368880640 |
|---|---|
| author | Feng Xu Xiaoling Huang Yangyi Li Yongsong Chen Ling Lin |
| author_facet | Feng Xu Xiaoling Huang Yangyi Li Yongsong Chen Ling Lin |
| author_sort | Feng Xu |
| collection | DOAJ |
| description | Lung adenocarcinoma (LUAD) is the most frequent subtype of lung cancer worldwide. However, the survival rate of LUAD patients remains low. N6-methyladenosine (m6A) and long noncoding RNAs (lncRNAs) play vital roles in the prognostic value and the immunotherapeutic response of LUAD. Thus, discerning lncRNAs associated with m6A in LUAD patients is critical. In this study, m6A-related lncRNAs were analyzed and obtained by coexpression. Univariate, least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression analyses were conducted to construct an m6A-related lncRNA model. Kaplan-Meier analysis, principal-component analysis (PCA), functional enrichment annotation, and nomogram were used to analyze the risk model. Finally, the potential immunotherapeutic signatures and drug sensitivity prediction targeting this model were also discussed. The risk model comprising 12 m6A-related lncRNAs was identified as an independent predictor of prognoses. By regrouping the patients with this model, we can distinguish between them more effectively in terms of the immunotherapeutic response. Finally, candidate compounds aimed at LUAD subtype differentiation were identified. This risk model based on the m6A-based lncRNAs may be promising for the clinical prediction of prognoses and immunotherapeutic responses in LUAD patients. |
| first_indexed | 2024-12-16T23:32:19Z |
| format | Article |
| id | doaj.art-89f0d859c0d340b3a6722bd387892b90 |
| institution | Directory Open Access Journal |
| issn | 2162-2531 |
| language | English |
| last_indexed | 2024-12-16T23:32:19Z |
| publishDate | 2021-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Molecular Therapy: Nucleic Acids |
| spelling | doaj.art-89f0d859c0d340b3a6722bd387892b902022-12-21T22:11:49ZengElsevierMolecular Therapy: Nucleic Acids2162-25312021-06-0124780791m6A-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with LUADFeng Xu0Xiaoling Huang1Yangyi Li2Yongsong Chen3Ling Lin4Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515041, China; Clinical Research Center, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515041, ChinaDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515041, China; Clinical Research Center, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515041, ChinaDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515041, China; Clinical Research Center, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515041, ChinaClinical Research Center, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515041, China; Department of Endocrinology, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515041, China; Corresponding author: Yongsong Chen, Department of Endocrinology, The First Affiliated Hospital of Shantou University Medical College, No. 57 Changping Road, Shantou, Guangdong 515041, China.Clinical Research Center, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515041, China; Department of Rheumatology, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515041, China; Corresponding author: Ling Lin, Department of Rheumatology, The First Affiliated Hospital of Shantou University Medical College, No. 57 Changping Road, Shantou, Guangdong 515041, China.Lung adenocarcinoma (LUAD) is the most frequent subtype of lung cancer worldwide. However, the survival rate of LUAD patients remains low. N6-methyladenosine (m6A) and long noncoding RNAs (lncRNAs) play vital roles in the prognostic value and the immunotherapeutic response of LUAD. Thus, discerning lncRNAs associated with m6A in LUAD patients is critical. In this study, m6A-related lncRNAs were analyzed and obtained by coexpression. Univariate, least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression analyses were conducted to construct an m6A-related lncRNA model. Kaplan-Meier analysis, principal-component analysis (PCA), functional enrichment annotation, and nomogram were used to analyze the risk model. Finally, the potential immunotherapeutic signatures and drug sensitivity prediction targeting this model were also discussed. The risk model comprising 12 m6A-related lncRNAs was identified as an independent predictor of prognoses. By regrouping the patients with this model, we can distinguish between them more effectively in terms of the immunotherapeutic response. Finally, candidate compounds aimed at LUAD subtype differentiation were identified. This risk model based on the m6A-based lncRNAs may be promising for the clinical prediction of prognoses and immunotherapeutic responses in LUAD patients.http://www.sciencedirect.com/science/article/pii/S2162253121000974N6-methyladenosinem6Along noncoding RNAslncRNAsprognosislung adenocarcinoma |
| spellingShingle | Feng Xu Xiaoling Huang Yangyi Li Yongsong Chen Ling Lin m6A-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with LUAD Molecular Therapy: Nucleic Acids N6-methyladenosine m6A long noncoding RNAs lncRNAs prognosis lung adenocarcinoma |
| title | m6A-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with LUAD |
| title_full | m6A-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with LUAD |
| title_fullStr | m6A-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with LUAD |
| title_full_unstemmed | m6A-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with LUAD |
| title_short | m6A-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with LUAD |
| title_sort | m6a related lncrnas are potential biomarkers for predicting prognoses and immune responses in patients with luad |
| topic | N6-methyladenosine m6A long noncoding RNAs lncRNAs prognosis lung adenocarcinoma |
| url | http://www.sciencedirect.com/science/article/pii/S2162253121000974 |
| work_keys_str_mv | AT fengxu m6arelatedlncrnasarepotentialbiomarkersforpredictingprognosesandimmuneresponsesinpatientswithluad AT xiaolinghuang m6arelatedlncrnasarepotentialbiomarkersforpredictingprognosesandimmuneresponsesinpatientswithluad AT yangyili m6arelatedlncrnasarepotentialbiomarkersforpredictingprognosesandimmuneresponsesinpatientswithluad AT yongsongchen m6arelatedlncrnasarepotentialbiomarkersforpredictingprognosesandimmuneresponsesinpatientswithluad AT linglin m6arelatedlncrnasarepotentialbiomarkersforpredictingprognosesandimmuneresponsesinpatientswithluad |